Eye-tracking data
ViewMind’s patented Digital Biomarker software, based on AI, can identify minor alterations in oculomotor patterns and correlate them to specific pathologies, cognitive functions and related areas of the brain
After completing a 15 minutes evaluation, the information is uploaded and processed in ViewMind’s cloud server, and the results are generated automatically within seconds.
Centralized
servers
Artificial
Intelligent
algorithms
Automatized
results
NEUROCOGNITIVE DIGITAL BIOMARKERS POWERED BY A.I.
ViewMind is a revolutionary digital health and AI company with clinically validated solutions for the early diagnosing of dementia
THE TECHNOLOGY
After conclusive clinical validation, ViewMind has established a unique degree of accuracy, with a 15 minutes test approach that can forever change the management of dementia.
Early Onset Screening
Validated on a longitudinal study, ViewMind is able to discriminate patients with Mild Cognitive Impairment who will develop Alzheimer’s or other neuro-degenerative diseases, years before Clinical Diagnostic
Digital Biomarker
ViewMind has higher Sensitivity and Specificity than Complete Neurocognitive Batteries and Complex Neuroimages. Clinical Protocols show levels of accuracy comparable with Spinal Fluid Extraction and a B- Amyloid PET in the early stages of Alzheimer’s, up to 20 years before symptoms.
THE SCIENCE
Gerardo Fernandez PhD
Matias Shulz
Neurocientific
Officer
CSO
CEO
Mario Parra M.D. PhD
David Orozco M.D.
Ariel Arelovich PhD
CMO
CTO
Executive
Chairman
Mark Edwards
Together with a third-party medical grade VR headset and specific stimuli, ViewMind 15-minutes evaluations can give actionable information for physicians to properly diagnose and define a course of action.
THE TEAM
